Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission
Top Cited Papers
Open Access
- 5 September 2013
- journal article
- Published by American Society of Hematology in Blood
- Vol. 122 (10), 1813-1821
- https://doi.org/10.1182/blood-2013-06-506725
Abstract
Key Points The negative impact of pre-HCT flow cytometrically determined MRD is similar for AML in CR1 and CR2. Even minute levels of MRD (≤0.1%) are associated with adverse outcome.Keywords
This publication has 21 references indexed in Scilit:
- Toward Optimization of Postremission Therapy for Residual Disease–Positive Patients With Acute Myeloid LeukemiaJournal of Clinical Oncology, 2008
- Graft-versus-disease effect following allogeneic transplantation for acute leukaemiaBest Practice & Research Clinical Haematology, 2008
- Monitoring of minimal residual disease in acute myeloid leukemiaCancer, 2007
- The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemiaLeukemia, 2006
- The effect of allogeneic stem cell transplantation on outcome in younger acute myeloid leukemia patients with minimal residual disease detected by flow cytometry at the end of post-remission chemotherapy2006
- National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. Diagnosis and Staging Working Group ReportTransplantation and Cellular Therapy, 2005
- Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid LeukemiaJournal of Clinical Oncology, 2003
- Pretransplant minimal residual disease level predicts clinical outcome in patients with acute myeloid leukemia receiving high-dose chemotherapy and autologous stem cell transplantationLeukemia, 2003
- Minimal residual disease in leukaemia patientsThe Lancet Oncology, 2001
- Antileukemic Effect of Graft-versus-Host Disease in Human Recipients of Allogeneic-Marrow GraftsNew England Journal of Medicine, 1979